Investigating basic information of skin toxicity associated with molecularly-targeted drugs cetuximab and panitumumab, and an evaluation of the usefulness of a topical moisturizer in patients treated for colorectal carcinoma and head and neck cancer.

Investigating basic information of skin toxicity associated with molecularly-targeted drugs cetuximab and panitumumab, and an evaluation of the usefulness of a topical moisturizer in patients treated for colorectal carcinoma and head and neck cancer. - Usefulness of a topical moisturizer for cetuximab and panitumumab-associated skin toxicity in patients with CRC and head and neck cancer.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019896

Enrollment

Registered

2015-11-23

Start date

2013-01-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal carcinoma and head and neck cancer

Interventions

topical administration of heparinoid twice a day in six weeks none

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Colorectal cancer or head and neck cancer patient administered cetuximab or panitumumab consent in writing

Exclusion criteria

Exclusion criteria: Patient treated with anti-EGFR antibody drugs before Patient with retinoid and/or retinoid analog within two weeks of observation period Patient with large skin problems such as burn, psoriasis, scleroderma Patient with drug eruption within two weeks of observation period Patient with hemorrhagic diseases such as hemophilia, thrombopenia, purpura Patient regarded as ineligible for clinical study by investigator

Design outcomes

Primary

Measure	Time frame
sebum capacity, water content of the stratum corneum, duaring 6 weeks from cetuximab or Panitumumab contained chemotherapy started	—

Secondary

Measure	Time frame
skin findings(skin dryness,desquamation), subjective complaints duaring 6 weeks from cetuximab or Panitumumab contained chemotherapy started	—

Countries

Japan

Contacts

Public ContactShoichi Watanabe

Nagoya city university Dermatology

wshoichi@med.nagoya-cu.ac.jp052-851-5511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026